La Alamedilla Health center
Welcome,         Profile    Billing    Logout  
 18 Trials 
23 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rodriguez, Jose F
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting
4
8600
US
Naltrexone-Bupropion (NB) Combination, Placebo
Currax Pharmaceuticals
Obesity
01/29
07/29
NCT05397600: Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Completed
3
684
Canada, US, RoW
Bimatoprost Ophthalmic
Laboratoires Thea
Glaucoma, Ocular Hypertension
03/24
03/24
REVERSE-IT, NCT04286438 / 2019-004457-92: Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

Completed
3
226
Europe, Canada, US, RoW
Bentracimab (PB2452) Infusion
SFJ Pharmaceuticals, Inc.
Hemorrhage, Urgent Surgery, Invasive Procedure
09/24
09/24
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
925
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
COMPASS, NCT05371613 / 2021-005200-35: A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

Recruiting
2/3
54
Europe, Canada, US, RoW
tividenofusp alfa, idursulfase
Denali Therapeutics Inc.
Mucopolysaccharidosis II
12/25
12/25
NCT06075537: An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Enrolling by invitation
2/3
99
Europe, Canada, US, RoW
tividenofusp alfa
Denali Therapeutics Inc.
Mucopolysaccharidosis II
06/27
06/27
NCT04579679 / 2020-006118-19: Open-Label Surufatinib in European Patients with NET

Completed
2
78
Europe, US
Surufatinib, HMPL-012, sulfatinib
Hutchmed
Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET
10/24
10/24
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Completed
2
48
US
AP-PA02, Placebo
Armata Pharmaceuticals, Inc.
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
07/24
08/24
NCT05979779: Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

Active, not recruiting
2
219
US
HU6, Placebo
Rivus Pharmaceuticals, Inc.
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
01/25
06/25
RESCUE, NCT05307328 / 2021-006184-19: SPI-62 As a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Active, not recruiting
2
26
Europe, US
SPI-62, Placebo
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
12/25
12/25
ACSPIRE, NCT05436639 / 2022-000748-32: SPI-62 As a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Terminated
2
30
Europe, US
SPI-62 dose
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
12/24
02/25
NCT05798520: A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Recruiting
2
275
Europe, US, RoW
BIIB091, DRF, Placebo
Biogen
Relapsing Forms of Multiple Sclerosis
09/27
09/27
NCT04812262: A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD

Completed
1
255
US
DD01, Placebo
Neuraly, Inc.
Overweight and Obesity, Type2 Diabetes, NAFLD
12/22
02/23
PROCEADE-CRC-01, NCT05464030: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Recruiting
1
200
Europe, Canada, Japan, US, RoW
M9140, Precemtabart tocentecan, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Colorectal Cancer
02/26
02/26
NCT06607185: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Recruiting
1
750
Europe, Japan, US, RoW
LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Eli Lilly and Company
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
01/30
01/30
STAR-GLOBAL, NCT04524416: MINIject Global Long-Term Follow-up Study

Recruiting
N/A
300
Europe, RoW
Minimally invasive glaucoma surgery (MIGS)
iSTAR Medical
Open Angle Glaucoma, Ocular Hypertension
12/25
12/25
Alonso, Maria del Mar
advance NEXT, NCT06544499: A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Recruiting
3
63
Europe, US
Efgartigimod IV, Placebo IV
argenx
Primary Immune Thrombocytopenia (ITP)
06/28
06/28
OLYMPIA-2, NCT06097364: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

Recruiting
3
733
Europe, US, RoW
Odronextamab, REGN1979, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Oncovin, Prednisone/Prenisolone, Deltasone/Omnipred
Regeneron Pharmaceuticals
Follicular Lymphoma (FL)
07/29
07/29
SHIELD, NCT05117840: Screening for High Frequency Malignant Disease

Active, not recruiting
N/A
12000
Europe, US
Low-dose CT scan
Guardant Health, Inc.
Lung Cancer
12/25
12/25
Rodríguez, José Manuel Ramírez
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
NCT05757102: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Recruiting
3
292
US, RoW
FF/UMEC/VI, ELLIPTA, FF/VI
GlaxoSmithKline
Asthma
01/27
01/27
Fernández, José A Maderuelo
NAGOMI COMPLEX, NCT05705973: Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients

Active, not recruiting
N/A
3000
Europe, RoW
Ultimaster Nagomi™
Terumo Europe N.V.
Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease
04/26
04/27
Sánchez, Emiliano Rodríguez
No trials found
Marcos, Manuel A Gomez
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rodriguez, Jose F
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting
4
8600
US
Naltrexone-Bupropion (NB) Combination, Placebo
Currax Pharmaceuticals
Obesity
01/29
07/29
NCT05397600: Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Completed
3
684
Canada, US, RoW
Bimatoprost Ophthalmic
Laboratoires Thea
Glaucoma, Ocular Hypertension
03/24
03/24
REVERSE-IT, NCT04286438 / 2019-004457-92: Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

Completed
3
226
Europe, Canada, US, RoW
Bentracimab (PB2452) Infusion
SFJ Pharmaceuticals, Inc.
Hemorrhage, Urgent Surgery, Invasive Procedure
09/24
09/24
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
925
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
COMPASS, NCT05371613 / 2021-005200-35: A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

Recruiting
2/3
54
Europe, Canada, US, RoW
tividenofusp alfa, idursulfase
Denali Therapeutics Inc.
Mucopolysaccharidosis II
12/25
12/25
NCT06075537: An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Enrolling by invitation
2/3
99
Europe, Canada, US, RoW
tividenofusp alfa
Denali Therapeutics Inc.
Mucopolysaccharidosis II
06/27
06/27
NCT04579679 / 2020-006118-19: Open-Label Surufatinib in European Patients with NET

Completed
2
78
Europe, US
Surufatinib, HMPL-012, sulfatinib
Hutchmed
Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET
10/24
10/24
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Completed
2
48
US
AP-PA02, Placebo
Armata Pharmaceuticals, Inc.
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
07/24
08/24
NCT05979779: Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

Active, not recruiting
2
219
US
HU6, Placebo
Rivus Pharmaceuticals, Inc.
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
01/25
06/25
RESCUE, NCT05307328 / 2021-006184-19: SPI-62 As a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Active, not recruiting
2
26
Europe, US
SPI-62, Placebo
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
12/25
12/25
ACSPIRE, NCT05436639 / 2022-000748-32: SPI-62 As a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Terminated
2
30
Europe, US
SPI-62 dose
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
12/24
02/25
NCT05798520: A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Recruiting
2
275
Europe, US, RoW
BIIB091, DRF, Placebo
Biogen
Relapsing Forms of Multiple Sclerosis
09/27
09/27
NCT04812262: A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD

Completed
1
255
US
DD01, Placebo
Neuraly, Inc.
Overweight and Obesity, Type2 Diabetes, NAFLD
12/22
02/23
PROCEADE-CRC-01, NCT05464030: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Recruiting
1
200
Europe, Canada, Japan, US, RoW
M9140, Precemtabart tocentecan, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Colorectal Cancer
02/26
02/26
NCT06607185: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Recruiting
1
750
Europe, Japan, US, RoW
LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Eli Lilly and Company
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
01/30
01/30
STAR-GLOBAL, NCT04524416: MINIject Global Long-Term Follow-up Study

Recruiting
N/A
300
Europe, RoW
Minimally invasive glaucoma surgery (MIGS)
iSTAR Medical
Open Angle Glaucoma, Ocular Hypertension
12/25
12/25
Alonso, Maria del Mar
advance NEXT, NCT06544499: A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Recruiting
3
63
Europe, US
Efgartigimod IV, Placebo IV
argenx
Primary Immune Thrombocytopenia (ITP)
06/28
06/28
OLYMPIA-2, NCT06097364: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

Recruiting
3
733
Europe, US, RoW
Odronextamab, REGN1979, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Oncovin, Prednisone/Prenisolone, Deltasone/Omnipred
Regeneron Pharmaceuticals
Follicular Lymphoma (FL)
07/29
07/29
SHIELD, NCT05117840: Screening for High Frequency Malignant Disease

Active, not recruiting
N/A
12000
Europe, US
Low-dose CT scan
Guardant Health, Inc.
Lung Cancer
12/25
12/25
Rodríguez, José Manuel Ramírez
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
NCT05757102: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Recruiting
3
292
US, RoW
FF/UMEC/VI, ELLIPTA, FF/VI
GlaxoSmithKline
Asthma
01/27
01/27
Fernández, José A Maderuelo
NAGOMI COMPLEX, NCT05705973: Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients

Active, not recruiting
N/A
3000
Europe, RoW
Ultimaster Nagomi™
Terumo Europe N.V.
Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease
04/26
04/27
Sánchez, Emiliano Rodríguez
No trials found
Marcos, Manuel A Gomez
No trials found

Download Options